Apr. 18 at 4:22 PM
$MDWD Claude:The More Likely Timeline
The acquisition-ready window is probably late 2027–2028 — after EscharEx Phase III data lands and MDWD is demonstrably tracking toward its
$50–55M revenue guidance with a clean regulatory profile from the new manufacturing facility. At that point, you’d expect a bidding dynamic between Mölnlycke (via its participation rights), Solventum (already a clinical partner), and potentially Coloplast or Vericel itself. Current ~
$250M market cap with
$831M EscharEx peak sales potential and a locked BARDA NexoBrid franchise would make for a very clean acquisition story at a 3–5x revenue multiple.
For 2026, M&A is a tail risk worth holding for, but not the base case to bet on.
